home / stock / bxrx / bxrx news


BXRX News and Press, Baudax Bio Inc. From 09/28/23

Stock Information

Company Name: Baudax Bio Inc.
Stock Symbol: BXRX
Market: NYSE

Menu

BXRX BXRX Quote BXRX Short BXRX News BXRX Articles BXRX Message Board
Get BXRX Alerts

News, Short Squeeze, Breakout and More Instantly...

BXRX - Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors

MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), a...

BXRX - Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), a...

BXRX - Baudax Bio files to sell 15M shares of common stock for holders.

2023-09-06 06:59:17 ET More on Baudax Bio Seeking Alpha’s Quant Rating on Baudax Bio Historical earnings data for Baudax Bio Financial information for Baudax Bio Baudax Bio announces $1.9M registered direct offering priced ATM For further detai...

BXRX - Baudax Bio announces $1.9M registered direct offering priced ATM

2023-08-17 08:33:07 ET More on Baudax Bio Baudax Bio stock dips on pricing $4M stock offering at $1.15/share Baudax Bio stock surges ~40% as neuromuscular blocker BX1000 shows promise in trial Baudax rises after mid-stage data for neuromuscular blocking agent ...

BXRX - Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromu...

BXRX - Baudax Bio GAAP EPS of -$1.49 beats by $0.55

2023-08-16 13:49:05 ET Baudax Bio press release ( NASDAQ: BXRX ): GAAP EPS of -$1.49 beats by $0.55 . As of June 30, 2023, Baudax Bio had cash and cash equivalents of $1.4 million. For further details see: Baudax Bio GAAP EPS of -$1.49 beats by $0.55

BXRX - Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace Announcement of Positive Top-Line Results from Phase 2 BX1000 Tr...

BXRX - Understanding Penny Stocks Breakout Patterns: 3 Tips 

2023-07-05 06:00:00 ET 3 Tips for Understanding Breakout Patterns With Penny Stocks Trading penny stocks can be an exciting and profitable endeavor for those who understand the game. Among the various strategies used by traders, one of the most intriguing is the identification of breako...

BXRX - AZN and VBIV among pre-market losers

2023-07-03 08:22:42 ET Baudax Bio ( BXRX ) -13% . VBI Vaccines ( VBIV ) -12% . Addentax Group ( ATXG ) -10% . AstraZeneca PLC ( AZN ) -7% . TOP Financial Group Limited ( TOP ) -4% . For further details see: AZN and VBIV amo...

BXRX - Analyze Penny Stocks Charts Like a Pro With These Tips 

2023-07-01 11:16:00 ET 3 Tips for Analyzing Penny Stocks Charts Like a Pro Navigating the world of penny stocks—those enticing equities trading at less than $5 per share—can be a rewarding yet complex endeavor. The high volatility that characterizes these assets offers uni...

Previous 10 Next 10